What are the guidelines for yellow fever vaccination?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Yellow Fever Vaccination Guidelines

Yellow fever vaccination requires a single subcutaneous injection of 0.5 mL of reconstituted vaccine that provides long-lasting immunity, with revaccination recommended every 10 years for those at continued risk of exposure. 1

Administration Requirements

  • Yellow fever vaccine must be administered at an approved Yellow Fever Vaccination Center 2
  • Vaccinees should receive an International Certificate of Vaccination or Prophylaxis (ICVP) that is:
    • Completed properly
    • Signed by the administering clinician
    • Stamped with the official stamp of the vaccination center 1
  • The vaccine should be administered within 1 hour of reconstitution 1
  • Once reconstituted, multidose vials should be maintained at 35°F–46°F (2°C–8°C), and remaining doses used or discarded within 1 hour 1

Dosage and Immunity Duration

  • A single 0.5 mL dose administered subcutaneously is sufficient for most individuals 1
  • While International Health Regulations formally require revaccination every 10 years, evidence suggests immunity persists for decades and may be lifelong 2, 3
  • If the date of most recent vaccination cannot be determined and the patient requires vaccination, a booster dose should be administered 1
  • Recent evidence shows that 94% of healthy adults in non-endemic settings maintain seroprotection even 10-60 years after vaccination 3

Special Populations and Contraindications

Contraindications:

  • Severe hypersensitivity to vaccine components, including egg proteins
  • Age <6 months (high risk of vaccine-associated neurologic disease)
  • Thymus disorders
  • Primary immunodeficiencies
  • Malignant neoplasms
  • Transplantation recipients
  • HIV with CD4 counts <200/mm³ or <15% of total lymphocytes for children <6 years 1

Precautions (require risk-benefit assessment):

  • Age 6-8 months (if travel to endemic area is unavoidable)
  • Adults ≥60 years (higher risk of serious adverse events with first-time vaccination)
  • Pregnancy
  • Breastfeeding
  • HIV with CD4 counts 200-499/mm³ or 15-24% of total lymphocytes for children <6 years
  • Family history of vaccine-associated adverse events 1

Adverse Events

  • Most reactions are mild: headaches, myalgia, low-grade fever for 5-10 days after vaccination 2
  • Serious adverse events are rare but include:
    • Yellow fever vaccine-associated neurotropic disease (YEL-AND)
    • Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) 1
  • All vaccinees should be observed for at least 15 minutes post-vaccination 1
  • Patients should be advised about potential allergic reaction symptoms and to seek immediate medical care if these develop 1

Special Considerations

Co-administration with other vaccines:

  • Inactivated vaccines can be administered simultaneously or at any time before/after yellow fever vaccine 1
  • Other live viral vaccines should be given either simultaneously or separated by 30 days 1

Blood donation:

  • Vaccinees should defer blood donation for 2 weeks after receiving yellow fever vaccine 1

Medical waivers:

  • For individuals with contraindications who must travel to endemic areas, healthcare providers should:
    • Complete the Medical Contraindications to Vaccination section of the ICVP
    • Provide a signed and dated exemption letter
    • Emphasize protective measures against mosquito bites 1

Special Population Considerations

  • Children: Lower seroprotection rates (47%) observed in children vaccinated at 9-23 months when measured 10+ years later 3
  • Older adults: Despite concerns about immunosenescence, a study of travelers vaccinated at age ≥60 found 100% remained seropositive 10 years after vaccination 4
  • HIV patients: Lower seroprotection rates (61%) observed 10+ years after vaccination 3

Yellow fever vaccination remains one of the most effective preventive measures against this potentially fatal disease, with a single dose providing robust protection for most individuals.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Yellow Fever Vaccination Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.